Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02363972 · ClinicalTrials.gov registry record · NA

Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD

A NA study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by Medtronic Endovascular.

Completed
Registry status
NA
Development phase
103
Enrollment target
5
Study locations

NCT02363972: Completed NA study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by Medtronic Endovascular.

NCT02363972 is a NA study of End Stage Renal Disease and End-Stage Kidney Disease that has completed, run by Medtronic Endovascular. The registered enrollment target is 103 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02363972, a NA study of End Stage Renal Disease and End-Stage Kidney Disease, has completed, sponsored by Medtronic Endovascular.

COMPLETED
Registry status
NA
Development phase
103 participants
Enrollment target
5
Study locations

Study Summary

A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.

Primary Outcome

Maturation success rate of the access site was a binary endpoint defined as (1) achievement of a venous diameter of greater than or equal to 4 mm and (2) blood flow greater than or equal to 500 ml/min as measured via duplex ultrasound at the 90 day follow-up visit for the ITT population.

Interventions

  • DEVICE Ellipsys Vascular Access Catheter

Study Locations (5)

Texas

  • Dallas Nephrology Associates - Plano
  • San Antonio Kidney Disease Center - San Antonio

Arizona

  • Southwest Vascular Center - Tempe

California

  • BNMG San Diego Vascular Access Center - San Diego

Virginia

  • Richmond Vascular Center - North Chesterfield

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2015-02-10
Est. Completion 2016-06
Phase NA
Medtronic Endovascular

25 total trials

What the finished NCT02363972 record still lists

NCT02363972 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower).

The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Ellipsys Vascular Access Catheter is the first listed.

NCT02363972 lists 5 locations in 4 states (Texas, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT02363972 about?

NCT02363972 is a clinical study titled "Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD". A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.

What is the current status of trial NCT02363972?

This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2015-02-10. Estimated completion is 2016-06.

What conditions does trial NCT02363972 study?

This clinical trial studies the following conditions: End Stage Renal Disease, End-Stage Kidney Disease, Fistula, AV Fistula.

What interventions are being tested in trial NCT02363972?

The interventions under investigation include: Ellipsys Vascular Access Catheter (DEVICE).

Who is sponsoring clinical trial NCT02363972?

This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02363972 being conducted?

This trial has 5 study locations across Arizona, California, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02363972's enrollment target sits among peer trials

103 33rd of 86 higher than 54 of 86 other End Stage Renal Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02363972, the US trial registry maintained by the National Library of Medicine. NCT02363972 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.